Comparison of effectiveness of cefovecin, doxycycline, and amoxicillin for the treatment of experimentally induced early Lyme borreliosis in dogs

BMC Veterinary Research

Patrick F. M. Meeus¹  Richard T. Marconi³  Thomas J. Heinz¹  John M. Hardham¹  Catherine Strietzel¹  Vickie King¹  Nicole Honsberger¹  David Garcia-Tapia¹  John Johnson¹  Bettina Wagner² 

[1]Veterinary Medicine Research and Development, Zoetis, 333 Portage Street, Kalamazoo 49007, MI, USA

[2]Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

[3]Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, Richmond 23298, VA, USA

关键词: Cefovecin;    Amoxicillin;    Doxycycline;    Borrelia burgdorferi;    Lyme Disease;   

Others  :  1224421
DOI  :  10.1186/s12917-015-0475-9

 received in 2014-10-30, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Background

While Koch’s postulates have been fulfilled for Lyme disease; causing transient fever, anorexia and arthritis in young dogs; treatment of sero-positive dogs, especially asymptomatic animals, remains a topic of debate. To complicate this matter the currently recommended antibiotic treatments of Lyme Disease in dogs caused by Borrelia burgdorferi require daily oral administrations for 31 days or longer, which makes non-compliance a concern. Additionally, there is no approved veterinary antimicrobial for the treatment of Lyme Disease in dogs in the USA and few recommended treatments have been robustly tested.

In vitro testing of cefovecin, a novel extended-spectrum cephalosporin, demonstrated inhibition of spirochete growth. A small pilot study in dogs indicated that two cefovecin injections two weeks apart would be as efficacious against B. burgdorferi sensu stricto as the recommended treatments using doxycycline or amoxicillin daily for 31 days.

This hypothesis was tested in 17–18 week old Beagle dogs, experimentally infected with B. burgdorferi sensu stricto, using wild caught ticks, 75 days prior to antimicrobial administration.

Results

Clinical observations for lameness were performed daily but were inconclusive as this characteristic sign of Lyme Disease rarely develops in the standard laboratory models of experimentally induced infection. However, each antibiotic tested was efficacious against B. burgdorferi as measured by a rapid elimination of spirochetes from the skin and reduced levels of circulating antibodies to B. burgdorferi. In addition, significantly less cefovecin treated animals had Lyme Disease associated histopathological changes compared to untreated dogs.

Conclusions

Convenia was efficacious against B. burgdorferi sensu stricto infection in dogs as determined by serological testing, PCR and histopathology results. Convenia provides an additional and effective treatment option for Lyme Disease in dogs.

【 授权许可】

   
2015 Wagner et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Littman MP, Goldstein RE, Labato MA, Lappin MR, Moore GE. ACVIM small animal consensus statement on Lyme disease in dogs: diagnosis, treatment, and prevention. J Vet Intern Med. 2006; 20(2):422-434.
• [2]Krupka I, Straubinger RK. Lyme borreliosis in dogs and cats: background, diagnosis, treatment and prevention of infections with Borrelia burgdorferi sensu stricto. Vet Clin North Am Small Anim Pract. 2010; 40(6):1103-1119.
• [3]Little SE, Heise SR, Blagburn BL, Callister SM, Mead PS. Lyme borreliosis in dogs and humans in the USA. Trends Parasitol. 2010; 26(4):213-218.
• [4]Van Vlaenderen I, Nautrup BP, Gasper SM. Estimation of the clinical and economic consequences of non-compliance with antimicrobial treatment of canine skin infections. Prev Vet Med. 2011; 99(2–4):201-210.
• [5]Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther. 2006; 29(6):501-511.
• [6]Stegemann MR, Passmore CA, Sherington J, Lindeman CJ, Papp G, Weigel DJ et al.. Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother. 2006; 50(7):2286-2292.
• [7]Appel MJ, Allan S, Jacobson RH, Lauderdale TL, Chang YF, Shin SJ et al.. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993; 167(3):651-664.
• [8]Summers BA, Straubinger AF, Jacobson RH, Chang YF, Appel MJ, Straubinger RK. Histopathological studies of experimental lyme disease in the dog. J Comp Pathol. 2005; 133(1):1-13.
• [9]Chang YF, Novosel V, Chang CF, Summers BA, Ma DP, Chiang YW et al.. Experimental induction of chronic borreliosis in adult dogs exposed to Borrelia burgdorferi-infected ticks and treated with dexamethasone. Am J Vet Res. 2001; 62(7):1104-1112.
• [10]Straubinger RK, Straubinger AF, Summers BA, Jacobson RH, Erb HN. Clinical manifestations, pathogenesis, and effect of antibiotic treatment on Lyme borreliosis in dogs. Wien Klin Wochenschr. 1998; 110(24):874-881.
• [11]Straubinger RK, Straubinger AF, Summers BA, Jacobson RH. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis. 2000; 181(3):1069-1081.
• [12]Susta L, Uhl EW, Grosenbaugh DA, Krimer PM. Synovial lesions in experimental canine Lyme borreliosis. Vet Pathol. 2012; 49(3):453-461.
• [13]Wagner B, Freer H, Rollins A, Garcia-Tapia D, Erb HN, Earnhart C et al.. Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs. Clin Vaccine Immunol. 2012; 19(4):527-535.
• [14]Levy SA, O’Connor TP, Hanscom JL, Shields P, Lorentzen L, Dimarco AA. Quantitative measurement of C6 antibody following antibiotic treatment of Borrelia burgdorferi antibody-positive nonclinical dogs. Clin Vaccine Immunol. 2008; 15(1):115-119.
• [15]Levy S, O’Connor TP, Hanscom JL, Shields P. Utility of an in-office C6 ELISA test kit for determination of infection status of dogs naturally exposed to Borrelia burgdorferi. Vet Ther. 2002; 3(3):308-315.
• [16]Littman MP. Lyme nephritis. J Vet Emerg Crit Care (San Antonio). 2013; 23(2):163-173.
• [17]Gerber B, Haug K, Eichenberger S, Reusch CE, Wittenbrink MM. Follow-up of Bernese Mountain dogs and other dogs with serologically diagnosed Borrelia burgdorferi infection: what happens to seropositive animals? BMC Vet Res. 2009; 5:18. BioMed Central Full Text
• [18]Gerber B, Eichenberger S, Haug K, Wittenbrink MM, Reusch CE. Association of urine protein excretion and infection with Borrelia burgdorferi sensu lato in Bernese Mountain dogs. Vet J. 2009; 182(3):487-488.
• [19]Horney BS, Stojanovic V. Protein-losing nephropathy associated with Borrelia burgdorferi seropositivity in a soft-coated wheaten terrier: response to therapy. Can Vet J. 2013; 54(4):392-396.
• [20]Goldstein RE, Brovida C, Fernandez-Del Palacio MJ, Littman MP, Polzin DJ, Zatelli A et al.. Consensus recommendations for treatment for dogs with serology positive glomerular disease. J Vet Intern Med. 2013; 27 Suppl 1:S60-S66.
• [21]Straubinger RK, Summers BA, Chang YF, Appel MJ. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol. 1997; 35(1):111-116.
• [22]Dever LL, Jorgensen JH, Barbour AG. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol. 1992; 30(10):2692-2697.
• [23]Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob Agents Chemother. 1993; 37(7):1444-1446.
• [24]Ruzic-Sabljic E, Podreka T, Maraspin V, Strle F. Susceptibility of Borrelia afzelii strains to antimicrobial agents. Int J Antimicrob Agents. 2005; 25(6):474-478.
• [25]Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol. 2003; 41(4):1791-1793.
• [26]Brissette CA, Kees ED, Burke MM, Gaultney RA, Floden AM, Watt JA. The multifaceted responses of primary human astrocytes and brain microvascular endothelial cells to the Lyme disease spirochete, Borrelia burgdorferi. ASN Neuro. 2013; 5(3):221-229.
• [27]Nicholson MC, Mather TN, Donnelly EF. Lyme disease in Rhode Island: three years of surveillance. Med Health Rhode Island. 1996; 79(8):311-313.
• [28]Rhodes DV, Earnhart CG, Mather TN, Meeus PF, Marconi RT. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design. Vet J. 2013; 198(2):412-418.